20226 ⎘
Medicinal preparations containing organic active ingredients; Amines Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
MELANOGENESIS INHIBITION COMPOSITIONS AND METHODS OF USE THEREOF
#2NOVEL NOOTROPIC PRODRUGS OF HENETHYLAMINE
#3COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION
#4DOSAGE REGIME WITH ESKETAMINE FOR TREATING NEUROPSYCHIATRIC OR NEUROLOGICAL CONDITIONS
#5SMALL MOLECULE BROAD-SPECTRUM ANTIBIOTICS
#6ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER
#7METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS, PULMONARY EDEMA, INTERSTITIAL LUNG DISEASE, SARCOIDOSIS, IDIOPATHIC PULMONARY FIBROSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, PULMONARY ARTERIAL HYPERTENSION, ADN RESPIRATORY SYNCYTIAL VIRUS
#8COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#92,6-DIBENZYLIDENECYCLOHEXANONE OXIME COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF
#10POLYINOSINIC- POLYCYTIDYLIC ACID COMPOSITIONS AND METHODS OF MAKING SAME
#11COMPOSITIONS AND METHODS USING TETRAHYDROCANNABINOL AND COMPOSITIONS INCLUDING SAME FOR TREATING INDICATIONS INVOLVING INFLAMMATION
#12METHODS OF MODULATING ENDONUCLEASE G USING RESVERATROL AND ITS DERIVATIVES
#13NOVEL POLYINOSINIC- POLYCYTIDYLIC ACID COMPOSITIONS
#14OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT
#15ANTIMICROBIAL TREATMENT AND PREVENTION BY PERILLYL ALCOHOL AND DERIVATIVES
#16ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER
#17Method Of Treating Major Depressive Disorder
#18COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#19FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS
#20METHOD OF TREATING MAJOR DEPRESSIVE DISORDER
#21METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT
#22COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
#23TREATMENT OF CIRCADIAN RHYTHM DISORDERS
#24METHOD OF INDUCING DENDRITIC AND SYNAPTIC GENESIS IN NEURODEGENERATIVE CHRONIC DISEASES
#25PHENYLETHYLIDENEHYDRAZINE DIMERS AND METHODS OF USING SAME
#26COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#27SYSTEMS AND METHODS FOR TREATMENT OF HEARING USING DIHEXA
#28DOSAGE REGIME WITH ESKETAMINE FOR TREATING MAJOR DEPRESSIVE DISORDER
#29METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES
#30TREATMENT OF CIRCADIAN RHYTHM DISORDERS
#31POLYFUNCTIONAL RADICAL SCAVENGER HYDROGEL FORMULATION
#32SUBSTITUTED PHENETHYLAMINE FOR TREATING INFLAMMATION AND PSYCHOLOGICAL DISORDERS
#33METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT
#34POLYFUNCTIONAL RADICAL SCAVENGER HYDROGEL FORMULATION
#35CARDIOPROTECTION BY AUTOPHAGY INDUCTION AND METABOLIC REPROGRAMMING
#36Precision Medicine Approach to Treating Parkinson's Disease with a Monoamine Oxidase Inhibitor, an Antioxidant, or Both
#37IMIDAZO[1,2-B]PYRIDAZINE BASED TRICYCLIC COMPOUNDS AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF
#38TREATMENT OF CIRCADIAN RHYTHM DISORDERS
#39METHODS AND COMPOSITIONS FOR MODULATING FGF ACTIVITY
#40COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
#41Treatment of circadian rhythm disorders
#42METALLOENZYME MODULATORS
#43Method Of Treating Major Depressive Disorder
#44Method Of Treating Major Depressive Disorder
#45Method of treating major depressive disorder
#46APPARATUS AND METHOD FOR PROTECTING NEURONS AND REDUCING INFLAMMATION AND SCARRING
#47Compounds and combinations thereof for treating neurological and psychiatric conditions
#48CLEAVABLE CONJUGATES OF CATECHOL COMPOUNDS AND WATER-SOLUBLE POLYMERS AND METHODS OF TREATMENT USING THE SAME
#49TREATMENT OF DERMATOLOGICAL CONDITIONS
#50METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4
#51P62-ZZ CHEMICAL INHIBITOR
#52MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING ANTITUMOR T CELL IMMUNITY
#53METHODS AND PHARMACEUTICAL COMPOSITION FOR TREATING DISEASES
#54NOVEL PSYCHEDELIC COMPOSITIONS, DELIVERY SYSTEMS AND THERAPEUTIC USES THEREOF
#55BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF
#56SUBCUTANEOUSLY IMPLANTED DEVICE FOR GASTROINTESTINAL ADMINISTRATION OF SUBSTANCES
#57Wound-care composition and method of use
#58Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
#59INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE
#60COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
#61COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#62COMPOUNDS FOR CHRONIC DISORDERS
#63Compositions and Methods for Treating COVID-19 and/or Acute Respiratory Failure and/or Acute Respiratory Distress Syndrome Using Tetrahydrocannabinol and Compositions Including Same
#64WATER-SOLUBLE ARTESUNATE-BASED THERAPY FOR CORONAVIRUS INFECTION
#65Dosage regime with esketamine for treating major depressive disorder
#66Method of treating major depressive disorder
#67DOSAGE REGIME WITH ESKETAMINE FOR TREATING MAJOR DEPRESSIVE DISORDER
#68Treatment of circadian rhythm disorders
#69PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING ANTIVIRAL AGENT AND ANTIDEPRESSANT AS ACTIVE INGREDIENTS
#70Methods for treating hearing loss incident to cochlear implant surgery
#71PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY
#72NEW MEDICAL TREATMENT
#73NOVEL POLYINOSINIC - POLYCYTIDYLIC ACID COMPOSITIONS AND METHODS OF MAKING SAME
#74BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#75Bupropion as a modulator of drug activity
#76NOVEL POLYINOSINIC - POLYCYTIDYLIC ACID COMPOSITIONS
#77Bupropion as a modulator of drug activity
#78Dosage regime with esketamine for treating major depressive disorder
#79Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy
#80PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME
#81Compositions and methods for reducing muscle contraction
#82DOSAGE REGIME WITH ESKETAMINE FOR TREATING NEUROPSYCHIATRIC OR NEUROLOGICAL CONDITIONS
#83SPINOSYN FORMULATIONS FOR TREATMENT OF DEMODEX-INDUCED OCULAR AND FACIAL CONDITIONS
#84Use of Glutamate 2B Receptor Antagonists and Sigma Receptor Agonists as Antitussives
#85METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY
#86VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH A CYP3A INHIBITOR AND AZACITIDINE
#87USE OF ANTIDEPRESSANT AGENTS FOR PREVENTING AND TREATING THE COVID-19 DISEASE
#88Substituted bicyclic compounds
#89Bupropion as a modulator of drug activity
#90Bupropion as a modulator of drug activity
#91ANTICANCER COMPOSITIONS AND METHODS FOR USING SAME
#92BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#93TREATMENT OF A RESPIRATORY CORONAVIRUS INFECTION WITH NITROXIDES
#94Methods and compositions for the treatment of neurological diseases and syndromes of aging
#95TARGETING SLC38A2 IN PANCREATIC CANCER
#96COMPOUNDS FOR PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION
#97PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY
#98ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS
#99Bupropion as a modulator of drug activity
#100Bupropion as a modulator of drug activity
#101Bupropion as a modulator of drug activity
#102BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#103Bupropion as a modulator of drug activity
#104OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT
#105Bupropion as a modulator of drug activity
#106METHODS OF TREATING MENTAL DISORDERS
#107Formulations of tegavivint and related compounds
#108Treatment of circadian rhythm disorders
#109Treatment of circadian rhythm disorders
#110Treatment of circadian rhythm disorders
#111TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS
#112Hydrazone amide derivatives and use thereof in preparation of anti-osteoporosis drugs
#113Method of treating major depressive disorder
#114COMPOSITIONS AND METHODS FOR TREATMENT OF DEPRESSION AND OTHER DISORDERS
#115Bupropion as a modulator of drug activity
#1161-carboxy-2-hydroxy-3-iminopropane and extraction method thereof
#117Bupropion as a modulator of drug activity
#118Targeting mitochondrial dynamics by mitochondrial fusion promoter M1 as a treatment strategy for nervous system injury
#119USE OF GERANYLFLAVONE A IN PREPARATION OF DRUG FOR PROMOTING HEALING OF WOUNDS
#120Bupropion as a modulator of drug activity
#121Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders
#122BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#123Methods, compositions and devices for treating cancer with illudofulvenes
#124Bupropion as a modulator of drug activity
#125METHODS FOR THE TREATMENT OF DEPRESSION
#126COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
#127COMBINED USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND HEMATOPOIETIC GROWTH FACTORS FOR TREATING HEMATOPOIETIC DISEASES
#128Methods for inducing an immune response
#129COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
#130Bupropion as a modulator of drug activity
#131Bupropion as a modulator of drug activity
#132Bupropion as a modulator of drug activity
#133Reducing Prominin2-Mediated Resistance to Ferroptotic Cell Death
#134Combination of dextromethorphan and bupropion for treating depression
#135ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER
#136Polyfunctional radical scavenger hydrogel formulation
#137Bupropion as a modulator of drug activity
#138Combination therapy using ascochlorin derivative
#139Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
#140Treatment of circadian rhythm disorders
#141METHODS FOR TREATING GAUCHER DISEASE
#142CYCLOBENZAPRINE TREATMENT FOR SEXUAL DYSFUNCTION
#143Method of modulating ribonucleotide reductase
#144COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACUTE AND CHRONIC PRURITIS
#145Compositions And Methods For Reducing Food Cravings
#146BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#147Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
#148METHODS FOR INHIBITING GROWTH OF ACSL4-OVEREXPRESSING TUMORS
#149METHOD OF TREATING POSTPRANDIAL INFLAMMATION
#150Method of treating major depressive disorder
#151Bupropion as a modulator of drug activity
#152Bupropion as a modulator of drug activity
#153Bupropion as a modulator of drug activity
#154Treatment of circadian rhythm disorders
#155BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#156METHOD OF TREATING CONDITIONS
#157Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same
#158Method of decreasing the fluctuation index of dextromethorphan
#159Bupropion as a modulator of drug activity
#160ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST
#161Bupropion as a modulator of drug activity
#162METHODS FOR TREATING DEMENTIA RELATED PSYCHOSIS
#163Treatment of circadian rhythm disorders
#164TREATMENT OF CIRCADIAN RHYTHM DISORDERS
#165Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide
#166METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS
#167Method Of Treating Post-Traumatic Stress Syndrome
#168TREATMENT FOR AGE- AND OXIDATIVE STRESS-ASSOCIATED MUSCLE ATROPHY AND WEAKNESS
#169Bupropion as a modulator of drug activity
#170Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
#171METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER
#172Methods of making novel pharmaceutical compositions
#173Bupropion as a modulator of drug activity
#174Pharmaceutical composition comprising particles and methods of making same
#175Use of minaprine to reduce tumor growth
#176Bupropion as a modulator of drug activity
#177Bupropion as a modulator of drug activity
#178Apparatus and method for protecting neurons and reducing inflammation and scarring
#179Bupropion as a modulator of drug activity
#180Bupropion as a modulator of drug activity
#181Combination of dextromethorphan and bupropion for treating depression
#182Bupropion as a modulator of drug activity
#183Bupropion as a modulator of drug activity
#184Bupropion as a modulator of drug activity
#185Bupropion as a modulator of drug activity
#186TRPA1 ANTAGONISTS FOR USE IN THE TREATMENT OF ATOPIC DERMATITIS
#187Bupropion as a modulator of drug activity
#188Treating and preventing diseases by modulating cell mechanics
#189Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy
#190Bupropion as a modulator of drug activity
#191CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS
#192Substituted bicyclic compounds
#193Polyfunctional radical scavenger hydrogel formulation
#194BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#195BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#196Bupropion as a modulator of drug activity
#197Bupropion as a modulator of drug activity
#198Bupropion as a modulator of drug activity
#199Bupropion as a modulator of drug activity
#200Bupropion as a modulator of drug activity
#201Bupropion as a modulator of drug activity
#202Bupropion as a modulator of drug activity
#203Bupropion as a modulator of drug activity
#204Bupropion as a modulator of drug activity
#205Bupropion as a modulator of drug activity
#206Bupropion as a modulator of drug activity
#207Methods and compositions for the treatment of obesity
#208TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT
#209COMBINATION THERAPY FOR CANCER
#210COMPOUNDS AND METHODS FOR INHIBITING CDK5 ALLEVIATE CARDIAC PHENOTYPES IN TIMOTHY SYNDROME AND RELATED CONDITIONS
#211Treatment of circadian rhythm disorders
#212Compositions and methods for reducing muscle contraction
#213NEW THERAPEUTIC USES OF ENZYME INHIBITORS
#214Method of treating major depressive disorder
#215DELIVERY OF AUTOLOGOUS CELLS COMPRISING MATRIX METALLOPROTEINASE FOR TREATMENT OF SCLERODERMA
#216METHODS OF TREATING LEUKODYSTROPHIES
#217METHODS OF ADMINISTERING PIRFENIDONE THERAPY
#218P62-ZZ chemical inhibitor
#219THERAPEUTIC SIGMA 1 RECEPTOR AGONISTS FOR TREATING LONG QT SYNDROME TYPE 1, TYPE 2, TYPE 6, TYPE 8 AND RELATED CHANNELOPATHIES
#220Treatment of circadian rhythm disorders
#221Antiviral compounds and methods
#222Methods for inducing an immune response
#223Formulations of tegavivint and related compounds
#2243-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
#225Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy
#226Methods for inducing an immune response by promoting premature termination codon read-through
#227Combination inhibiting MEIS proteins
#228TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT
#229Motor control function improving agent
#230Hypothermia Ameliorating Agent
#231Process and apparatus of producing beverge
#232COMPOSITIONS AND METHODS FOR INHIBITING GROWTH OF ACSL4-OVEREXPRESSING TUMORS
#233METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS
#234D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof
#235TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT
#236METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING
#237Bupropion as a modulator of drug activity
#238Use of Sigma-1 receptor agonist compounds
#239Opioid agonist antagonist combinations
#240Bupropion as a modulator of drug activity
#241METHODS OF ADMINISTERING PIRFENIDONE THERAPY
#242Methods for treating Gaucher disease
#243Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents
#244Treatment of circadian rhythm disorders
#245Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
#246Methods of treating mental disorders
#247Biomarkers for diagnosing post traumatic stress disorder
#248SHELLAC MICROCAPSULE FORMULATIONS AND COMPOSITIONS
#249Methods for inducing an immune response by inhibition of nonsense mediated decay
#250Substituted bicyclic compounds
#251Treatment of circadian rhythm disorders
#252Treating and preventing diseases by modulating cell mechanics
#253NEW DRUG FOR THE TREATMENT AND/OR PREVENTION OF DEPRESSIVE DISORDERS
#254PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME
#255ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF
#256Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
#257MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer
#258Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#259Methods and compositions for treatment of demyelinating diseases
#260METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
#261COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
#262Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
#263COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
#264Method for treating hemolytic uremic syndrome
#265Therapy and kit for the prevention and treatment of cystic fibrosis
#266TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT
#267METHODS OF ADMINISTERING PIRFENIDONE THERAPY
#268Derivatives used in the treatment of muscle atrophy
#269Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use
#270Adjuvant chemotherapy for anaplastic gliomas
#271Modulators of mitochondrial protein import
#272Compositions and methods for reducing muscle contraction
#273MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER
#274SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS
#275METHODS OF TREATMENT OF, AND FORMULATIONS FOR TREATMENT OF ANORECTAL AND GENITOURINARY CONDITIONS
#276PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
#277Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#278Treatment of circadian rhythm disorders
#279METHODS OF REDUCING IMMUNE CELL ACTIVATION AND USES THEREOF
#280METHODS OF ADMINISTERING PIRFENIDONE THERAPY
#281COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
#282Multi-Step Connective Tissue Stabilization Method and Stabilized Tissue Formed Thereby
#283FIBROTIC TISSUE STABILIZED BY CROSSLINKING FOR TREATMENT OF SNORING AND OBSTRUCTIVE SLEEP APNEA
#284Bupropion as a modulator of drug activity
#285Compounds for reactivation of acetylcholinesterase and related compositions methods and systems
#286COMPOSITIONS AND METHODS FOR REDUCING FOOD CRAVINGS
#287Substituted bicyclic compounds
#288Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#289TREATMENT OF CIRCADIAN RHYTHM DISORDERS
#290Methods for predicting drug responsiveness
#291Methods for treating brain injury
#292Antiviral compounds and methods
#293CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS
#294METHOD FOR ANTICOAGULATION
#295Polymeric nitrones and their use in personal care
#296Methods of Administering Pirfenidone Therapy
#297TREATMENT OF COGNITIVE IMPAIRMENT
#298Immunoregulatory agents
#299Small molecule efflux pump inhibitors
#300Treatment of circadian rhythm disorders